<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407043</url>
  </required_header>
  <id_info>
    <org_study_id>Donnenfeld Review 1</org_study_id>
    <nct_id>NCT00407043</nct_id>
  </id_info>
  <brief_title>Multicenter, Randomized, Controlled Study of the Effect of Lotemax on Initiation of Dry Eye Treatment With Restasis</brief_title>
  <official_title>A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ophthalmic Consultants of Long Island</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ophthalmic Consultants of Long Island</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the impact of Lotemax on the initiation of Restasis therapy in patients with dry&#xD;
      eye.&#xD;
&#xD;
      It is hypothesized that the anti-inflammatory activity of Lotemax may help mitigate the&#xD;
      stinging with cyclosporine administration and the dry eye signs and symptoms experienced&#xD;
      during the initiation of therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dry eye is an ocular surface disease that produces discomfort and irritation. Estimated&#xD;
      prevalence ranges from 20 million people in the US being affected with mild to moderate dry&#xD;
      eye, to as many as one out of every five Americans.&#xD;
&#xD;
      A growing body of evidence has associated ocular inflammation with the signs and symptoms of&#xD;
      dry eye.&#xD;
&#xD;
      Restasis is indicated to increase tear production in patients whose tear production is&#xD;
      presumed to be suppressed due to ocular inflammation associated with a condition called&#xD;
      keratoconjunctivitis sicca. The relief of dry eye signs and symptoms with Restasis therapy is&#xD;
      often delayed by 1 to 6 months from the initiation of therapy. Stinging on installation,&#xD;
      particularly when initiating therapy, has been reported.&#xD;
&#xD;
      Lotemax, an ophthalmic corticosteroid, targets inflammation with a unique, site-active&#xD;
      mechanism of action.Structural modifications associated with an ester ophthalmic steroid make&#xD;
      Lotemax highly lipid soluble, enhancing penetration into cells and enabling Lotemax to exert&#xD;
      anti-inflammatory activity within the eye. Lotemax is indicated for the treatment of steroid&#xD;
      responsive inflammatory conditions associated with the palpebral and bulbar conjunctiva,&#xD;
      cornea, and anterior segment of the globe.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ocular Surface Disease Questionnnaire Results</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Lissamine green staining</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Fluorescein Staining</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Schirmer testing</measure>
  </primary_outcome>
  <enrollment type="Actual">5</enrollment>
  <condition>Dry Eye Disease</condition>
  <condition>Keratoconjunctivitis Sicca</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lotemax</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restasis</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between the ages of 30 and 80 inclusive.&#xD;
&#xD;
          -  Has not worn contact lenses for at least 1 month prior to the study and agrees to not&#xD;
             wear contact lenses during study.&#xD;
&#xD;
          -  Oral medications stable 1 month prior to study.&#xD;
&#xD;
          -  Oral medications anticipated to be stable during 60 day study.&#xD;
&#xD;
          -  Patient is in generally good &amp; stable overall health.&#xD;
&#xD;
          -  Patient likely to comply with eye drop regimen, study guidelines &amp; study visits.&#xD;
&#xD;
          -  Corneal stain &gt; 1+ or Conjunctival stain &gt; 1+ or OSDI equal or &gt; 5 or using regular&#xD;
             artificial tears at least on average twice daily.&#xD;
&#xD;
          -  Informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of Stevens-Johnson Syndrome or Ocular Pemphigoid.&#xD;
&#xD;
          -  Punctal plugs inserted or punctal cautery in the past 3 months.&#xD;
&#xD;
          -  Intra-ocular surgery within 6 months or ocular laser surgery within 3 months.&#xD;
&#xD;
          -  History of liver disease.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Severe clinical vitamin deficiencies or history of vitamin overdose.&#xD;
&#xD;
          -  Highly variable vitamin intake.&#xD;
&#xD;
          -  Unstable use of systemic or topical medications known to create dry eye.&#xD;
&#xD;
          -  Corneal pathology, which could, of itself, cause an ocular surface disorder.&#xD;
&#xD;
          -  Use of glaucoma medications, topical or oral.&#xD;
&#xD;
          -  Unstable diabetes mellitus.&#xD;
&#xD;
          -  Allergy or sensitivity to Lotemax, Restasis or the OTC Tear Supplement.&#xD;
&#xD;
          -  Use of topical steroids or Restasis within the past 1 month.&#xD;
&#xD;
          -  Use of other topical ocular agents other than tear replacements within the past 1&#xD;
             week.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Howard</last_name>
    <role>Study Director</role>
    <affiliation>Ophthalmic Consultants of Long Island</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Lynbrook</city>
        <state>New York</state>
        <zip>11563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Eric Donnenfeld</name_title>
    <organization>OCLI</organization>
  </responsible_party>
  <keyword>Dry Eye Disease</keyword>
  <keyword>Lotemax</keyword>
  <keyword>Restasis</keyword>
  <keyword>Loteprednol</keyword>
  <keyword>Cyclosporine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
    <mesh_term>Keratoconjunctivitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Loteprednol Etabonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

